PLN 9.49
(-4.33%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 90.47 Million PLN | -17.5% |
2022 | 109.66 Million PLN | -16.24% |
2021 | 130.92 Million PLN | -15.92% |
2020 | 155.7 Million PLN | 15.23% |
2019 | 135.12 Million PLN | 31.73% |
2018 | 102.57 Million PLN | -24.91% |
2017 | 136.6 Million PLN | 56.09% |
2016 | 87.51 Million PLN | 32.78% |
2015 | 65.91 Million PLN | -86.36% |
2014 | 483.32 Million PLN | 106.43% |
2013 | 234.13 Million PLN | -89.07% |
2012 | 2.14 Billion PLN | 32462.22% |
2011 | 6.57 Million PLN | 282.47% |
2010 | 1.71 Million PLN | 306.55% |
2009 | 422.94 Thousand PLN | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 46.85 Million PLN | -48.21% |
2024 Q3 | 43.28 Million PLN | -14.72% |
2024 Q2 | 50.75 Million PLN | 8.33% |
2023 Q4 | 90.47 Million PLN | -18.75% |
2023 Q3 | 111.36 Million PLN | 67.46% |
2023 FY | 90.47 Million PLN | -17.5% |
2023 Q1 | 105.61 Million PLN | -3.69% |
2023 Q2 | 66.5 Million PLN | -37.03% |
2022 FY | 109.66 Million PLN | -16.24% |
2022 Q4 | 109.66 Million PLN | -28.62% |
2022 Q3 | 153.62 Million PLN | 73.43% |
2022 Q2 | 88.58 Million PLN | -17.27% |
2022 Q1 | 107.07 Million PLN | -18.22% |
2021 Q4 | 130.92 Million PLN | -25.58% |
2021 Q3 | 175.91 Million PLN | -10.06% |
2021 Q2 | 195.59 Million PLN | 12.38% |
2021 FY | 130.92 Million PLN | -15.92% |
2021 Q1 | 174.04 Million PLN | 11.78% |
2020 Q1 | 141.08 Million PLN | 4.41% |
2020 FY | 155.7 Million PLN | 15.23% |
2020 Q2 | 139.47 Million PLN | -1.14% |
2020 Q3 | 142.15 Million PLN | 1.93% |
2020 Q4 | 155.7 Million PLN | 9.53% |
2019 Q3 | 113.88 Million PLN | 5.91% |
2019 Q4 | 135.12 Million PLN | 18.65% |
2019 Q2 | 107.52 Million PLN | 6.29% |
2019 Q1 | 101.16 Million PLN | -1.38% |
2019 FY | 135.12 Million PLN | 31.73% |
2018 Q3 | 96.25 Million PLN | -5.6% |
2018 FY | 102.57 Million PLN | -24.91% |
2018 Q4 | 102.57 Million PLN | 6.57% |
2018 Q2 | 101.96 Million PLN | -69.08% |
2018 Q1 | 329.7 Million PLN | 141.36% |
2017 FY | 136.6 Million PLN | 56.09% |
2017 Q1 | 98.9 Million PLN | 13.01% |
2017 Q2 | 130.37 Million PLN | 31.82% |
2017 Q3 | 125.01 Million PLN | -4.11% |
2017 Q4 | 136.6 Million PLN | 9.27% |
2016 FY | 87.51 Million PLN | 32.78% |
2016 Q2 | 66.61 Million PLN | -7.87% |
2016 Q3 | 79.98 Million PLN | 20.07% |
2016 Q4 | 87.51 Million PLN | 9.42% |
2016 Q1 | 72.3 Million PLN | 9.69% |
2015 FY | 65.91 Million PLN | -86.36% |
2015 Q4 | 65.91 Million PLN | -20.08% |
2015 Q3 | 82.47 Million PLN | 24.88% |
2015 Q2 | 66.03 Million PLN | 17.49% |
2015 Q1 | 56.2 Million PLN | -88.37% |
2014 FY | 483.32 Million PLN | 106.43% |
2014 Q4 | 483.32 Million PLN | 639.41% |
2014 Q2 | 40.16 Million PLN | 44.56% |
2014 Q1 | 27.78 Million PLN | -88.13% |
2014 Q3 | 65.36 Million PLN | 62.75% |
2013 Q1 | 20.43 Million PLN | -99.05% |
2013 Q2 | 18.66 Million PLN | -8.63% |
2013 Q3 | 19.2 Million PLN | 2.86% |
2013 Q4 | 234.13 Million PLN | 1119.24% |
2013 FY | 234.13 Million PLN | -89.07% |
2012 Q4 | 2.14 Billion PLN | 12303.46% |
2012 FY | 2.14 Billion PLN | 32462.22% |
2012 Q3 | 17.26 Million PLN | 0.0% |
2011 FY | 6.57 Million PLN | 282.47% |
2010 FY | 1.71 Million PLN | 306.55% |
2009 FY | 422.94 Thousand PLN | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Bioceltix S.A. | 2.26 Million PLN | -3888.315% |
BIOTON S.A. | 215.86 Million PLN | 58.086% |
Captor Therapeutics Spolka Akcyjna | 28.07 Million PLN | -222.284% |
Molecure S.A. | 11.34 Million PLN | -697.536% |
NanoGroup S.A. | 1.49 Million PLN | -5971.954% |
Pharmena S.A. | 1.9 Million PLN | -4647.009% |
Poltreg S.A. | 39.58 Million PLN | -128.589% |
Pure Biologics Spólka Akcyjna | 20.84 Million PLN | -334.051% |
Ryvu Therapeutics S.A. | 120.36 Million PLN | 24.827% |
Synthaverse S.A. | 153.26 Million PLN | 40.966% |
Urteste S.A. | 1.85 Million PLN | -4777.52% |